The study will examine how testosterone treatment influences daily activities and various symptoms that patients may experience. These activities include personal care tasks, while the symptoms being monitored include physical conditions such as fatigue, pain, and breathing difficulties, as well as emotional well-being. The medication will be given through intravenous administration, and patients will be monitored over time to assess any improvements in their overall condition and independence in daily activities.

During the study, healthcare providers will regularly assess patients’ ability to perform everyday tasks and their general well-being. The assessment will include monitoring how well patients can take care of themselves and how they feel in terms of various physical and emotional symptoms. The study will also consider feedback from people close to the patients about changes in their quality of life.

Participants in the study will receive either Midazolam or Morphine through injections, which can be given intravenously (into a vein), subcutaneously (under the skin), or intramuscularly (into a muscle). The study will monitor how quickly symptoms are relieved after the medication is administered and will also track any adverse reactions, such as nausea, vomiting, or hallucinations. The study aims to provide valuable information on the effectiveness and safety of these medications in managing end-of-life symptoms.

The trial will take place over a period of time, with each participant being observed for up to 14 days. The information gathered will help healthcare providers better understand the relationship between the dosage of these medications and their impact on symptom control and side effects. This study is an important step in improving the quality of care for elderly patients in their final days.

The purpose of the study is to gather evidence on whether this cannabis extract can improve symptoms compared to a placebo. Participants in the study will take the treatment orally for a period of up to eight weeks. During this time, their symptoms will be monitored and compared to those of a group receiving a placebo. The study aims to assess changes in symptoms such as pain, sleep quality, and overall distress, using tools like the Edmonton Symptom Assessment System and other quality-of-life questionnaires.

The results of this trial will help determine the effectiveness of the Cannabis Extract Avextra 10/10 Solution in managing symptoms for cancer patients in palliative care. This information could be used to plan future studies and potentially improve treatment options for patients experiencing significant symptom burdens due to cancer.

The purpose of this research is to evaluate whether medium to high doses of psilocybin therapy are safe and effective in reducing depression symptoms compared to low doses in patients with these conditions. Participants will receive two doses of the medication during the study, with evaluations of their depression symptoms occurring before treatment and six weeks after the second dose.

During the study, patients will be monitored for changes in their psychological well-being, including their ability to cope with end-of-life concerns, overall quality of life, and general mental health. The study will also look at how the treatment affects the stress levels and daily responsibilities of those caring for the patients. The treatment period will last approximately two months, with follow-up evaluations to track the participants’ progress.

Participants in the study will receive Paracetamol either under the skin or through a vein, and researchers will compare how the medication is absorbed and processed in the body. This will help determine the best way to administer Paracetamol to manage pain effectively in palliative care patients. The study will also monitor the patients’ pain levels using a simple numerical scale and check for any skin reactions or other side effects during the treatment period.

The trial will last for a period of up to 30 days, during which time the safety and effectiveness of the two methods of administering Paracetamol will be closely observed. The study aims to provide valuable information that could improve pain management for patients in palliative care, ensuring they receive the most effective and comfortable treatment possible.